Adastra Pharmaceuticals Overview

  • Founded
  • 2005

Founded
  • Status
  • Acquired/​Merged

  • Employees
  • 2

Employees
  • Latest Deal Type
  • M&A

Adastra Pharmaceuticals General Information

Description

Developer of proprietary medicines designed to offer treatment for cancer. The company's medicines include an oral multi-kinase inhibitor which combines the benefits of inhibiting important cyclin-dependent kinases equipotently, enabling healthcare professionals to ensure the survival of their patients and increase their quality of life.

Contact Information

Formerly Known As
Tragara Pharmaceuticals
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Parent Company
Primary Office
  • 2929 Campus Drive
  • Suite 230
  • San Mateo, CA 94403
  • United States
+1 (760) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Adastra Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Merger/Acquisition 07-Sep-2021 000.00 Completed Clinical Trials - Phase 1
10. Later Stage VC (Series B) 25-Jan-2021 0000 Cancelled Clinical Trials - Phase 1
9. Later Stage VC (Series B) 24-Apr-2019 00.000 000.00 0000 Completed Clinical Trials - Phase 1
8. Later Stage VC (Series A) 15-Nov-2016 00.000 000.00 000.00 Completed Pre-Clinical Trials
7. Later Stage VC (Series 3) 01-Sep-2015 000.00 000.00 000.00 Completed Pre-Clinical Trials
6. Later Stage VC (Series 2) 03-Sep-2013 0000 0000 000.00 Completed Pre-Clinical Trials
5. Later Stage VC 08-Aug-2012 000 0000 0000 Completed Pre-Clinical Trials
4. Grant 26-Mar-2010 000 0000 Completed Pre-Clinical Trials
3. Later Stage VC (Series 1) 04-Feb-2010 $5M $53M 0000 Completed Pre-Clinical Trials
2. Early Stage VC (Series 1) 15-Mar-2007 $40M $48M 0000 Completed Pre-Clinical Trials
To view Adastra Pharmaceuticals’s complete valuation and funding history, request access »

Adastra Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 0.00
Series A 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series 3 0,000,000 00.000000 00.00 00.0 00.0 00 00.0 00.000
Series 2 3,199,449 $0.000100 $0.32 $4 $4 1x $4 11.24%
Series 1 4,374,998 $0.000100 8% $10 $10 1x $10 15.37%
To view Adastra Pharmaceuticals’s complete cap table history, request access »

Adastra Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of proprietary medicines designed to offer treatment for cancer. The company's medicines include an oral multi
Drug Discovery
San Mateo, CA
2 As of 2021
000.00
000000&0 000.00

000000

exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in repre
0000 000000000
Saint Louis, MO
00.000
00000000000 00.000

000000

e irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excep
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Adastra Pharmaceuticals Competitors (21)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Euclises Venture Capital-Backed Saint Louis, MO 00.000 00000000000 00.000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
0000000 000 Corporation New York, NY 000 00000 00000000 00000
000000000 00000000 Venture Capital-Backed South San Francisco, CA 00 000.00 0000000000 0 000.00
000000000 00000000 Venture Capital-Backed Duisburg, Germany 0 000.00 00000000000 000.00
You’re viewing 5 of 21 competitors. Get the full list »

Adastra Pharmaceuticals Patents

Adastra Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-9120815-B2 Solid state forms of macrocyclic kinase inhibitors Active 05-Feb-2010 0000000000
US-20130150378-A1 Solid state forms of macrocyclic kinase inhibitors Granted 05-Feb-2010 0000000000
ES-2632548-T3 Solid state forms of macrocyclic kinase inhibitors Active 05-Feb-2010 0000000000
EP-2531197-A1 Solid state forms of macrocyclic kinase inhibitors Granted 05-Feb-2010 0000000000 0
EP-2531197-B1 Solid state forms of macrocyclic kinase inhibitors Active 05-Feb-2010 C07D498/06
To view Adastra Pharmaceuticals’s complete patent history, request access »

Adastra Pharmaceuticals Executive Team (10)

Name Title Board Seat Contact Info
Jillian Chapas-Reed Vice President of Clinical Operations
Lynne Rollins Chief Financial Officer
You’re viewing 2 of 10 executive team members. Get the full list »

Adastra Pharmaceuticals Board Members (12)

Name Representing Role Since
Dennis Podlesak Domain Associates Board Member 000 0000
Eckard Weber MD Domain Associates Board Member 000 0000
Grigory Borisenko Adastra Pharmaceuticals Board Member 000 0000
Mauro Bove Self Board Member 000 0000
Ralph Christoffersen Ph.D Morgenthaler Ventures Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Adastra Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Adastra Pharmaceuticals Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Domain Associates Venture Capital Minority 000 0000 000000 0
Lightstone Ventures Venture Capital Minority 000 0000 000000 0
Mitsubishi International Corporation Minority 000 0000 000000 0
Morgenthaler Ventures Venture Capital Minority 000 0000 000000 0
Multiple Myeloma Research Foundation Corporation Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »